問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

693Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1743Cases

2021-06-14 - 2022-05-13

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2021-07-21 - 2023-03-29

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting
A phase 3, randomized, multicenter, open-label trial comparing velzatinib (GSK6042981) with imatinib in participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

  • Condition/Disease

    Previously untreated metastatic and/or unresectable gastrointestinal stromal tumors

  • Test Drug

    Imatinib tablets 100mg Imatinib tablets 400mg Velzatinib (GSK6042981) Tablets 100mg

Participate Sites
5Sites

Not yet recruiting1Sites

2018-09-26 - 2022-05-18

Phase III

Active
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

  • Condition/Disease

    Unresectable Locally Advanced Urothelial Cancer Metastatic Urothelial Cancer

  • Test Drug

    Durvalumab (MEDI4736)/TREMELIMUMAB

Participate Sites
7Sites

Recruiting6Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A randomized, double-blind, parallel-group, phase 3 trial was conducted to evaluate the efficacy, safety, and tolerability of elecoglipron compared to placebo in adult patients with type 2 diabetes, impaired renal function, and receiving background treatment with dapagliflozin (Eluminate-4).

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
12Sites

Not yet recruiting1Sites

2018-12-06 - 2026-03-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

  • Condition/Disease

    Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor Gastro-enteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm Neuroendocrine Carcinoma

  • Test Drug

    CVM-1118 Capsules

Participate Sites
8Sites

Recruiting3Sites

Terminated4Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2026-07-01 - 2028-11-30

Phase II

Not yet recruiting
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Advanced Gastrointestinal (GI) Cancers

  • Condition/Disease

    Gastrointestinal Cancers

  • Test Drug

    Rina‑S

Participate Sites
5Sites

Not yet recruiting1Sites

2018-07-30 - 2020-09-30

Phase III

Completed
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer Metastatic Gastric Adenocarcinoma or Cancer Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
9Sites

Recruiting6Sites

Terminated1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

2018-07-01 - 2023-06-02

Phase III

Completed
A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER

  • Condition/Disease

    Early Breast Cancer

  • Test Drug

    PHESGO

Participate Sites
4Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

陳訓徹
Linkou Chang Gung Medical Foundation

2018-06-26 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion

  • Condition/Disease

    Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

  • Test Drug

    Venetoclax

Participate Sites
7Sites

Recruiting6Sites

1 5 6 7 8 9 175
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB